Valeant, Pershing Square settle insider trading cases for 0M After playing defense against insider trading allegations for several years, Valeant and Pershing Square are settling with Allergan investors for $290 […]
Judge overturns 0M AndroGel verdict against AbbVie Ever since AbbVie took its first major loss in its AndroGel liability litigation—a $150 million verdict back in July—the drugmaker has insisted that […]
Could a three-part diabetes drug ease memory loss in Alzheimer’s? The Alzheimer’s field is littered with drug-development failures, but that isn’t deterring a group of British scientists from looking for […]
Bioengineers mimic natural development to create complex living tissues The field of tissue engineering has advanced to the point where bioengineers can use 3D printing to grow human tissues like […]
Using an old Merck drug, Menlo hopes to scratch an itch with M IPO Six months after getting off a $50 million series C, late-stage California dermatology biotech Menlo Therapeutics […]
Fresenius oncology drug plant slammed with new warning letter A Fresenius Kabi cancer drug plant in India savaged by the FDA in the past for hiding serious drug testing issues, […]
A CAR-T approach to attacking HIV Engineered immune cells known as chimeric antigen receptor T cells (CAR-T) have grabbed headlines this year for their potential to cure some patients with […]
Mallinckrodt inks .2B Sucampo buy, ending rough 2017 on a high note Mallinckrodt, which has landed in hot water multiple times this year, is diversifying beyond its controversial lead seller. […]
Roche snags another Perjeta combo nod, but will ‘weak’ data limit its use? Roche landed an end-of-the-year indication for Perjeta, but it’s an indication analysts and investors think may not […]
Using CRISPR to prevent hearing loss The emerging gene-editing technique CRISPR-Cas9 is being examined for its potential to prevent hearing loss in people who inherit faulty deafness-causing genes. Scientists at […]